Patel Mahesh V. 4
4 · Lipocine Inc. · Filed Dec 17, 2020
Insider Transaction Report
Form 4
Lipocine Inc.LPCN
Patel Mahesh V.
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2020-12-16+45,000→ 1,243,090 total - Award
Stock Option (Right to Buy)
2020-12-15$1.37/sh+375,000$513,750→ 375,000 totalExercise: $1.37From: 2021-12-15Exp: 2030-12-15→ Common Stock (375,000 underlying) - Exercise/Conversion
Restricted Stock Unit
2020-12-16+45,000→ 45,000 totalExercise: $0.00From: 2020-12-16Exp: 2027-01-25→ Common Stock (45,000 underlying) - Sale
Common Stock
2020-12-16$1.35/sh−15,000$20,250→ 1,228,090 total
Footnotes (4)
- [F1]Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 15, 2021, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years.
- [F2]Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO.
- [F3]Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units.
- [F4]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.